COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00031187
Recruitment Status : Completed
First Posted : February 28, 2002
Last Update Posted : October 24, 2011
Information provided by:
Seattle Genetics, Inc.

Brief Summary:
SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory prostate cancer who have not had any prior therapy with Taxotere or Novantrone. Both SGN-15 and Taxotere will be administered weekly over two 6 week courses separated by a 2 week rest period.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Drug: SGN-15 (cBR96-doxorubicin immunoconjugate) Drug: Taxotere (docetaxel) Phase 2

Detailed Description:
The purpose of this study is to evaluate a new class of biologic agent, the monoclonal antibody (mAb) drug conjugate SGN-15 (cBR96 - Doxorubicin immunoconjugate), used in combination with the taxane agent, TAXOTERE (docetaxel) as a strategy for targeting advanced stage, hormone refractory prostate carcinoma (HRPC). This is a randomized, open label, phase II study evaluating the immunoconjugate SGN-15 in combination with the taxane TAXOTERE in comparison to TAXOTERE alone in patients with HRPC. Based on a previous phase I study of the SGN-15/TAXOTERE combination, the weekly dose of SGN-15 will be 200 mg/m2 and the weekly dose of TAXOTERE will be 35 mg/m2. The schedule of administration for both agents will be weekly, with SGN-15 administered prior to the TAXOTERE in the patients treated with the combination. A single course of therapy will be defined as 6 weekly doses followed by a 2 week rest period for a total of 8 weeks. The study will perform an interim analysis of the data after 80 patients have completed two courses. Patients should be treated for a minimum of 2 courses of therapy. Additionally, for patients who remain eligible and have experienced tolerable levels of drug toxicity, repeat dosing with subsequent cycles is possible. Patients will be removed from study if there is evidence of tumor progression or intolerable toxicity. Follow-up assessments include adverse event reporting, clinical laboratory studies, and quality of life (QOL) assessment using a validated QOL instrument.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Taxotere in Patients With Hormone Refractory Prostate Carcinoma
Study Start Date : October 2000
Actual Study Completion Date : July 2003

Resource links provided by the National Library of Medicine

Drug Information available for: Doxorubicin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


Patients must have pathologically confirmed prostate cancer, which is refractory to hormone therapy. There must be evidence of advancing disease, determined by increasing bidimensional or unidimensional measurable tumor or an increasing PSA with documented metastatic disease.

Patients must have Lewis(Y) antigen expression documented by immunohistochemistry on archived or fresh tumor specimen.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00031187

Layout table for location information
United States, Arizona
Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, Arkansas
Highlands Oncology Group
Springdale, Arkansas, United States, 72764
United States, California
West Los Angeles - VA Healthcare Center
Los Angeles, California, United States, 90073
VA Medical Center of Palo Alto
Palo Alto, California, United States, 94304
Sharp HealthCare, Sidney Kimmel Cancer Center
San Diego, California, United States, 92121
United States, Connecticut
Bendheim Cancer Center
Greenwich, Connecticut, United States, 06830
United States, Florida
Florida Cancer Specialists
Fort Myers, Florida, United States, 33901
Broward Oncology Associates
Ft. Lauderdale, Florida, United States, 33308
Innovative Medical Research of South Florida
Miami Shores, Florida, United States, 33138
United States, Michigan
St. Joseph Mercy Oakland Hospital
Pontiac, Michigan, United States, 33308
United States, Virginia
Arlington Fairfax Hematology-Oncology, P.C.
Arlington, Virginia, United States, 22205
Sponsors and Collaborators
Seattle Genetics, Inc.
Layout table for investigator information
Study Director: Andrew Sandler, MD Seattle Genetics, Inc.

Additional Information:
Layout table for additonal information Identifier: NCT00031187    
Obsolete Identifiers: NCT00028470
Other Study ID Numbers: SG0001-015
First Posted: February 28, 2002    Key Record Dates
Last Update Posted: October 24, 2011
Last Verified: October 2011
Keywords provided by Seattle Genetics, Inc.:
Lewis Blood-Group System
Antibodies, Monoclonal
Antigens, Neoplasm
Antineoplastic Agents
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Liposomal doxorubicin
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors